Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Details

Serval ID
serval:BIB_6C0868CDA7D6
Type
Article: article from journal or magazin.
Collection
Publications
Title
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Journal
Journal of Urology
Author(s)
Schurch B., de Sèze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., Plante P., Perrouin-Verbe B., Kumar C., Fraczek S., Brin M.F.
Working group(s)
Botox Detrusor Hyperreflexia Study Team
ISSN
0022-5347 (Print)
ISSN-L
0022-5347
Publication state
Published
Issued date
2005
Volume
174
Number
1
Pages
196-200
Language
english
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
PURPOSE: We determined the safety and efficacy of each of 2 doses of botulinum toxin type A (BTX-A) (200 or 300 U BOTOX) injected into the detrusor for urinary incontinence caused by neurogenic detrusor overactivity of predominantly spinal cord origin.
MATERIALS AND METHODS: A total of 59 patients with urinary incontinence caused by neurogenic detrusor overactivity (due to spinal cord injury in 53 and multiple sclerosis in 6) requiring clean intermittent self-catheterization were randomized to receive a single dose into the detrusor of BTX-A (200 U or 300 U) or placebo. Changes in daily frequency of urinary incontinence episodes were monitored via a patient bladder diary during 24 weeks. Key urodynamic assessments (maximum cystometric capacity, reflex detrusor volume and maximum detrusor pressure during bladder contraction) were used to provide objective measures of the treatment effect on bladder function. The impact of treatment on quality of life was assessed using the Incontinence Quality of Life questionnaire.
RESULTS: There were significant posttreatment decreases in incontinence episodes from baseline in the 2 BTX-A groups (p </=0.05) but not in the placebo group. In addition, more patients who received BTX-A reported no incontinence episodes during at least 1 posttreatment evaluation period. Positive treatment effects were also reflected by significant improvements in bladder function in the BTX-A groups, as assessed by urodynamics and in patient quality of life. Benefits were observed from the first evaluation at week 2 to the end of the 24-week study. No safety concerns were raised.
CONCLUSIONS: Intramuscular injections of BTX-A into the detrusor can provide rapid, well tolerated, clinically significant decreases in the signs and symptoms of urinary incontinence caused by neurogenic detrusor overactivity during a 24-week study period.
Keywords
Adult, Aged, Botulinum Toxins, Type A/therapeutic use, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuromuscular Agents/therapeutic use, Time Factors, Urinary Bladder, Neurogenic/complications, Urinary Bladder, Neurogenic/drug therapy, Urinary Incontinence/drug therapy, Urinary Incontinence/etiology
Pubmed
Web of science
Create date
05/11/2014 12:13
Last modification date
20/08/2019 14:26
Usage data